These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15247979)

  • 1. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor.
    Tobu M; Iqbal O; Fareed D; Chatha M; Hoppensteadt D; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):225-32. PubMed ID: 15247979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
    Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients.
    Taylor JE; Belch JJ; McLaren M; Henderson IS; Stewart WK
    Kidney Int; 1993 Jul; 44(1):182-90. PubMed ID: 8355460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
    J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced thrombin activatable fibrinolysis inhibitor and enhanced proinflammatory cytokines in acute coronary syndrome.
    Pang H; Zhang C; Liu F; Gong X; Jin X; Su C
    Med Intensiva; 2017 Nov; 41(8):475-482. PubMed ID: 28038785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
    Colucci M; Semeraro N
    Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M; Özbek M; Akbal E; Üreten K
    Turk J Med Sci; 2019 Oct; 49(5):1381-1385. PubMed ID: 31549496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of combined vascular endothelial growth factor, endothelial nitric oxide synthase and thrombin-activatable fibrinolysis inhibitor genetic polymorphisms among Egyptian patients with recurrent spontaneous abortion.
    Abulata NN; Shaheen IA; Osman OM; Hussein AM; El-Khayat WM
    J Obstet Gynaecol Res; 2019 Jun; 45(6):1106-1113. PubMed ID: 30968528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional immunosurveillance study of anti-EPO antibody levels in CRF patients receiving epoetin alfa in 5 Ontario Renal Centers.
    Wu G; Wadgymar A; Wong G; Ting R; Nathoo B; Mendelssohn D; Pandeya S; Sapir D; Tam P
    Am J Kidney Dis; 2004 Aug; 44(2):264-9. PubMed ID: 15264184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
    Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between inflammation,coagulation/fibrinolysis and vascular access in hemodialysis patients.
    Costa E; Rocha S; Rocha-Pereira P; Castro E; Reis F; Teixeira F; Miranda V; Do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    J Vasc Access; 2008; 9(4):248-53. PubMed ID: 19085894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH; van Tilburg NH; Vos HL; Bertina RM; Rijken DC
    Br J Haematol; 2004 Mar; 124(5):659-65. PubMed ID: 14871254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients.
    Kalantar-Zadeh K; McAllister CJ; Lehn RS; Lee GH; Nissenson AR; Kopple JD
    Am J Kidney Dis; 2003 Oct; 42(4):761-73. PubMed ID: 14520627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population.
    Akatsu H; Ishiguro M; Ogawa N; Kanesaka T; Okada N; Yamamoto T; Campbell W; Okada H
    Microbiol Immunol; 2007; 51(5):507-17. PubMed ID: 17579260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia.
    Colucci M; Simioni P; Piro D; Prandoni P; Pagnan A; Semeraro N
    Haematologica; 2003 Dec; 88(12):1383-9. PubMed ID: 14687992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates?
    Standage BA; Schuman ES; Ackerman D; Gross GF; Ragsdale JW
    Am J Surg; 1993 May; 165(5):650-4. PubMed ID: 8488954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.